Supplemental Programming

As a registered 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting attendee, you will be automatically registered for this exclusive, post-meeting supplemental programming, taking place over the course of four days in late February and early March.

Thursday, February 25, 2021

On-demand link coming soon for registered attendees.
From First-in-Human to Reimbursement:  A Practical Guide to PET Tracer Development 
Sponsored by the SNMMI Radiopharmaceutical Sciences Council
Organizers: Steven Liang, PhD; Pedro Brugarolas, PhD
Moderators: Steven Liang, PhD; Pedro Brugarolas, PhD


The first presentation will discuss the quality control requirements for a tracer that will go into humans and the documentation that needs to be included in the Chemistry, Manufacturing and Controls (CMC) Section of an Investigational New Drug (IND) application to the FDA. We will discuss specific examples and common problems and solutions. The second presentation will discuss other data typically included in the IND application such as dosimetry, toxicology and previous animal and human experience. We will also discuss general considerations for the design of first-in-human studies including common study objectives, typical number of subjects and other considerations (e.g., imaging dynamically or statically, using an arterial input function, evaluating radiometabolites, performing single or multiple scans, doing focused imaging or whole body imaging).  And the third presentation will discuss the design of phase II and phase III studies including study objectives, typical number of subjects, number of scans per subject, imaging protocol (e.g. static imaging without blood sampling). We will also discuss the documentation required for approval from the FDA.   Learning objectives: Have a good understanding of what is an IND and its parts Have a good understanding of the requirements of each IND section Learn the objectives of phase I/II/III clinical trials for PET radiopharmaceuticals Learn about the general principles in the design of clinical trials with PET radiopharmaceuticals

Objectives

  • Describe the parts of an IND application including the quality control requirements of a PET radiopharmaceutical for administration to human subjects
  • Define other requirements of an IND including dosimetry estimation, toxicology and prior animal and human experience 
  • List the steps involved in the advancement of PET radiopharmaceuticals from first in human studies to FDA approval and reimbursement


12:00–12:25 pm ET
Tracer Synthesis in a cGMP Lab
Michael L. Nickels, PhD
Washington University School of Medicine
St. Louis, MO

12:25–12:50 pm ET
First-in-Human Studies
Corinne Beinat, PhD
Stanford University School of Medicine
Stanford, CA

12:50–1:15 pm ET
Phase II/III and FDA Approval
David M. Schuster, MD, FACR
Emory University School of Medicine
Atlanta, GA

1:15–1:30 pm ET
Q&A


Tuesday, March 2, 2021

12:00–1:00 pm ET

Clinical Application of Advances in Whole-Body SPECT and SPECT/CT
Sponsored by the SNMMI General Clinical Nuclear Medicine Council; Physics, Instrumentation and Data Sciences Council
Organizers: Gad S. Abikhzer, MDCM, FRCPC, ABNM
Moderator: R. Glenn Wells, PhD


This session will review the principles and clinical applications of advances in SPECT and SPECT/CT. Specifically, the session will review the advances in SPECT and SPECT/CT software and hardware to effectively implement optimal acquisition protocols such as whole-body SPECT, reconstruction, quantitation and optimal CT acquisitions. Clinical applications such as whole-body bone SPECT acquisition protocols, advantages and clinical applications with its evidence will be reviewed and compared with NaF PET/CT for bone imaging.

Objectives

  • Recognize advances in SPECT and SPECT/CT technologies for rapid quantitative imaging
  • Utilize technological advances to improve on acquisition protocols
  • Discuss clinical applications of SPECT and SPECT/CT for general nuclear medicine and bone imaging


12:00–12:25 pm ET
Technical Advances in SPECT and SPECT/CT 
Chi Liu, PhD
Yale University 
New Haven, CT

12:25–12:50 pm ET
Clinical Applications of Advances in Whole-Body SPECT and SPECT/CT
Gad S. Abikhzer, MDCM, FRCPC, ABNM 
McGill University 
Montreal, QC, Canada

12:50–1:00 pm
Q&A


Wednesday, March 3, 2021

12:00–1:30 pm ET

Nuts and Bolts–Using PET's New Imaging Agents
Sponsored by the SNMMI Clinical Trials Network
Organizers: Regan I. Butterfield Schuchart, BS,CNMT, ARRT(CT); John M. Hoffman, MD
Moderator: Amanda Abbott


The year 2020 will be one for the history books thanks to Covid-19 but there were some bright spots for molecular imaging, namely 3 new imaging agents. This nuts and bolts session will review three newly approved PET imaging agents–18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE. 18F-FES is approved for the detection of estrogen receptor positive lesions in metastatic or recurrent breast cancer. 18F-flortaucipir is indicated for PET imaging of the brain to estimate tau burden in adults with cognitive impairment being evaluated for Alzheimer’s Disease. 64Cu-DOTATATE is the first product approved with the 64Cu isotope and is indicated for localization of NETs in adults.  The session will review the agents’ availability, who to image, how to use, and when to use.

Objectives

  • List the indications for 18F-FES, 18F -flortaucipir, and 64Cu-DOTATATE
  • Choose appropriate patients for 18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE imaging
  • Discuss how and where to acquire 18F-FES, 18F-flortaucipir, and 64Cu-DOTATATE doses

Speakers
Farrokh Dehdashti, MD, Washington University, St. Louis
Erik Mittra, MD, PhD, Oregon Health & Science University
Val J. Lowe, MD, Mayo Clinic, Rochester


Tuesday, March 16, 2021

7:00–8:30 pm ET
Advances in Imaging of the Thyroid and Parathyroid
Sponsored by the SNMMI Correlative Imaging Council; General Clinical Nuclear Medicine Council; PET Center of Excellence
Organizers: Thomas A. Hope, MD; Christopher J. Palestro, MD, FSNMMI; Rathan Subramaniam, MD, PhD, MPH, FACNM, FSNMMI; Twyla B. Bartel, DO, MBA, FACNM 
Moderator: Thomas A. Hope, MD


Molecular and radiological imaging, such as ultrasound and CT, play complimentary roles in the characterization and localization of thyroid and parathyroid pathology.  This comprehensive session is designed for imaging specialists, investigators, technologists, and clinicians, who want both a review of the status of parathyroid and imaging as well as an update on new and emerging developments in the field.  This first part of this course will include reviews of state-of-the-art ultrasound, 4D-CT, and 99mTc sestamibi SPECT/CT for preoperative parathyroid lesion localization, including their indications, advantages, and disadvantages. The potential of positron emitting agents such 18F-fluorocholine, will also be discussed.  The second part of this session will review state of the art thyroid imaging as well as the use of TI-RADS for thyroid nodule evaluation. This session will illustrate the value of integrating radiological and molecular imaging for treatment planning.

Objectives

  • Discuss how conventional imaging (US and CT) are used to image parathyroid and thyroid diseases
  • Review the role of sestamibi SPECT and thyroid scintigraphy in the localization and characterization of disease
  • Compare the benefits of fluorocholine PET to existing approaches for localization parathyroid adenomas


7:00–7:15 pm ET
US and CT for Imaging Parathyroids
Twyla B. Bartel, DO, MBA, FACNM 
Global Advanced Imaging
Tulsa, OK

7:15–7:30 pm ET
Imaging Parathyroids with Sestamibi
Christopher J. Palestro, MD, FSNMMI 
Zucker School of Medicine at Hofstra/Northwell 
Spring Valley, NY

7:30–7:45 pm ET
Fluorocholine PET for Parathyroid Adenomas
Luka Lezaic, MD, PhD
University Medical Centre Ljubljana
Ljubljana, Slovenia

7:45–8:00 pm ET
Brief Overview of TI-RADS
Tara Morgan, MD
University of California School of Medicine
San Francisco, CA

8:00–8:15 pm ET
Thyroid Scintigraphy
Anca M. Avram, MD, FACNM
University of Michigan Medical Center
Ann Arbor, MI

8:15–8:30 pm
Q&A